Thymosin Beta-4
Symbol T4 · MW 4964 Da
Naturally occurring peptide that promotes tissue repair and regeneration.
- Discovered
- 1981
- Half-life
- 1 hour
- Approval
- Not FDA-approved
Quick facts
- Category
- Recovery
- Route
- Injectable
- Molecular weight
- 4964 Da
- Half-life
- 1 hour
- Discovered
- 1981
- Approval status
- Not FDA-approved
Reported effects
- Tissue repair
- Anti-inflammatory
- Cardiac & neuro recovery
Overview
Thymosin Beta-4 is a naturally occurring peptide involved in tissue repair, wound healing, cell migration, and inflammation control. It helps regulate actin, a structural protein that allows cells to move and repair damaged tissue. Thymosin Beta-4 is studied for skin healing, corneal repair, cardiac injury research, and soft-tissue recovery. Its purpose is to support repair-related biological pathways rather than simply mask discomfort. As a recovery peptide, Thymosin Beta-4 is often connected to wound healing, tissue regeneration, inflammation reduction, and improved recovery after injury.
Evidence context
Thymosin Beta-4 evidence summary
Human clinical evidence
Thymosin Beta-4 has an approval context listed in the Peptidic database. Approved use still depends on the specific indication, formulation, labeling, and clinician guidance.
Animal, preclinical, or formulation evidence
Thymosin Beta-4 may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for Thymosin Beta-4 as Not FDA-approved. The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- No established approved dosage; commonly referenced range is 2–10 mg weekly
- Typical Frequency
- 2–3 times weekly
Dosing depends on the approved indication, formulation, titration schedule, and clinician guidance. This page is educational and not a substitute for medical advice.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on Thymosin Beta-4.
Internal links
Related peptides
Frequently asked questions
What category is Thymosin Beta-4 in?
Thymosin Beta-4 is listed in the Recovery category on Peptidic.
What route is Thymosin Beta-4 associated with?
Thymosin Beta-4 is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is Thymosin Beta-4 approved?
Peptidic lists the approval status for Thymosin Beta-4 as: Not FDA-approved. Approval details can vary by indication and jurisdiction.
Interested in Thymosin Beta-4?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01